Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2006

View Archived Issues

Hunter's syndrome patients benefit from idursulfase infusions

Defibrotide demonstrates anticancer potential

Preclinical insulinotropic efficacy and stability of novel GLP-1 and GIP analogues reported

Crucell and VRC begin phase I study of Ebola vaccine

Pfizer acquires license to gene RTP-801 with relevance to AMD

Kalypsys advancing KD-3010 for metabolic disorders

MacuSight studies proprietary formulation of sirolimus in diabetic macular edema

VQD-001 studied in phase I/II solid tumor study

AN-2690 demonstrates efficacy in phase II onychomycosis study

QR-333 administered safely in subjects with diabetic peripheral neuropathy

Contrave achieves greater weight loss than placebo with no sign of plateau

Satraplatin meets progression-free survival endpoint in SPARC trial

InterMune files to begin phase I program for HCV protease inhibitor ITMN-191

Millennium to acquire AnorMED

Pericor Science makes advance in thrombin inhibitor research

Elan and Transition Therapeutics collaborate on AZD-103 for Alzheimer's

ACV-1 enters phase II for neuropathic pain

Survival benefit for AS-1404 in NSCLC

First sales for seasonal influenza vaccine Anflu in China

R&D highlights from the UBS Global Life Sciences Conference in New York: NeurogesX

Rasilez filed for European approval

Abraxane submitted for breast cancer in Europe

LN-1-255: a novel beta-lactamase inhibitor

Preclinical update on DC-159a: a promising fluoroquinolone for treatment of respiratory infections

New PDK1 inhibitors from Berlex described

L-90268: a novel prostanoid EP4 receptor agonist with ocular hypotensive activity

New NK2 receptor antagonist with potential use in IBS

New therapeutic agents for HIV infection disclosed in recent Tibotec and Shionogi patents

Recent patents report novel analgesic agents

Novel agents for inflammatory disorders disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...